Privacy Policy
Signals Blog

Contributors

Categories

Cell Therapy Deal Review: August

by | Sep 30, 2015

. Welcome to your cell therapy deal review for the month of August. Synthetic biology giant Intrexon closed a large financing; Immune Design announced a collaboration to pair its viral-based immunotherapy platform with a checkpoint inhibitor; and, NantKwest received a...

Update from the Clinic: August

by | Sep 29, 2015

. Welcome to your Update from the Clinic for the month of August. The adult stem cell community enjoyed a much needed confidence boost after TiGenix announced its Phase 3 trial hit its primary endpoint. Northwest confirmed its Phase 3 trial of DCVax in glioblastoma is...

The tiny fingers that touch stem cells

by | Sep 22, 2015

. I was reading Nature the other day and came across a neat article from Yukikio Yamashita’s group at the University of Michigan entitled Nanotubes mediate niche–stem-cell signalling in the Drosophila testis. It may not sound interesting to our average reader, but the...

The waiting game: First human iPSC clinical trial on hold

by | Sep 1, 2015

. Nicole Forgione is a post-doctoral fellow working in the Fehlings group at the Toronto Western Research Institute. Currently she holds a Toronto Western Research Institute Fellowship to support her work on cell-based regenerative therapies for traumatic spinal cord...

Update from the Clinic: July

by | Aug 25, 2015

. Welcome to your update from the Clinic for the month of July. Adaptimmune moves a second candidate into the clinic. Ziopharm receives an Orphan Drug Designation for its cutting edge IL-12 technology. Canadian cell therapy company, Hemostemix, keeps moving forward...